Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription

Rhea-AI Summary

Haleon has launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction (ED) in the U.S. Available for pre-order on Amazon and in major retailers by October 2024, Eroxon® is clinically proven to help men achieve erections within 10 minutes. This fast-acting treatment addresses a significant unmet need, as existing prescription solutions can take up to an hour to work.

Clinical studies demonstrate Eroxon®'s safety and efficacy for men with ED. The gel stimulates nerve endings in the penis to aid in achieving and maintaining erections. Haleon aims to make this accessible treatment available to millions of American men affected by ED, emphasizing the importance of sexual health in overall wellness.

Positive

• First FDA-cleared OTC gel for erectile dysfunction in the U.S.
• Clinically proven to work within 10 minutes, faster than existing prescription solutions
• Available for pre-order on Amazon, with wide retail distribution planned for October 2024
• Addresses a significant unmet need in the ED treatment market
• Expands Haleon's product portfolio into the sexual health space

Negative

• None.

Insights

Medical Research Analyst

Haleon's launch of Eroxon®, the first FDA-cleared OTC gel for erectile dysfunction (ED), marks a significant milestone in sexual health treatment. The gel's rapid onset of action (within 10 minutes) addresses a important unmet need, potentially disrupting the market dominated by prescription medications with longer onset times.

Clinical studies demonstrating Eroxon®'s safety and efficacy in men with ED are promising. However, it's important to note that the product's long-term effects and potential interactions with other medications remain to be seen in real-world usage. The gel's mechanism of action, stimulating nerve endings in the penis, differs from oral ED medications, which could lead to a different side effect profile.

The OTC availability could significantly increase accessibility for millions of men affected by ED, potentially leading to improved quality of life and relationships. However, this also raises concerns about proper usage and the potential for men to bypass important medical consultations that could identify underlying health issues causing ED.

Market Research Analyst

Haleon's entry into the sexual health market with Eroxon® represents a strategic move to tap into a lucrative segment. The global erectile dysfunction market was valued at $3.9 billion in 2022 and is projected to grow at a CAGR of 6.8% from 2023 to 2030. As the first OTC option, Eroxon® could capture a significant market share, especially among younger men who may be hesitant to seek prescription treatments.

The product's availability through major retailers and Amazon pre-orders indicates a robust distribution strategy. However, success will depend on effective marketing to overcome potential stigma and educate consumers about this new treatment option. The October 2024 launch timing allows for a comprehensive awareness campaign.

Investors should monitor initial sales figures and consumer reception closely, as these will be important indicators of Eroxon®'s market penetration and Haleon's potential revenue growth in this new segment. The product's performance could significantly impact Haleon's stock valuation in the coming years.

• Eroxon^® is Haleon's first offering in the sexual health space
  
• Clinical studies show Eroxon^® is safe and effective in men with ED
  
• Eroxon^® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024

WARREN, N.J., Sept. 3, 2024 /PRNewswire/ -- Eroxon^®, the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.

Eroxon^® is clinically proven to help men get an erection within 10 minutes to foster physical intimacy (individual results may vary). The treatment stimulates nerve endings in the penis to help men with ED get and maintain an erection during sex. Given existing prescription solutions may take up to an hour to work (based on labels), Eroxon^® addresses a significant unmet need for men experiencing ED.

Clinical study results show that Eroxon^® is safe and effective in men with ED. While ED can be caused by underlying physical conditions, psychological challenges such as stress, anxiety, depression, and other mental health issues may also contribute to ED, especially in younger men. Eroxon^® aims to help men with ED enhance intimacy and connection in their relationships, fostering closer and more fulfilling partnerships.

Lisa Paley, President, North America at Haleon, said: "At Haleon, we have a clear purpose to deliver better everyday health with humanity. Introducing Eroxon to U.S. consumers reflects our belief that sexual health is a critical part of wellness. We understand how important making meaningful and intimate connections are to one's wellbeing, and Eroxon helps achieve just that. We are proud to take this bold step to make this first-of-its-kind over-the-counter (OTC) gel treatment accessible to the millions of men in the U.S. who are affected by ED."

Gerald Brock, MD, FRCSC, Haleon Partner, said: "The body of scientific evidence for Eroxon supports it as an effective, fast-acting, and accessible OTC ED treatment with an excellent safety profile."

How to use Eroxon^®:

• Unscrew cap. Pierce the tube seal with top of cap.
• Squeeze tube firmly to empty all the contents onto finger(s), which will provide the correct dose.
• Massage the gel onto the head of your penis for about 15 seconds. If you are uncircumcised, gently pull your foreskin back as far as comfortable before applying the gel. It may take a few attempts to achieve the desired effect.
•  You can apply the gel, or your partner can apply the gel to your penis as part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, which resulted in better outcomes.

For more information on Eroxon^® and ED, visit eroxon.us, and to preorder visit Amazon.

About Erectile Dysfunction
ED is a common condition, impacting 1 in 4 men over the age of 22¹ – that's 30 million men.² Men with ED may have trouble getting or maintaining an erection firm enough for sexual activity. Some men have trouble on occasion, while others may not be able to get an erection at all. ED typically becomes more prevalent as you age, impacting half of men over the age of 40.³ However, mild-to-moderate symptoms often go undetected and untreated, especially in younger men. For more information about erectile dysfunction (ED), please visit our website eroxon.us.

About Eroxon^®
Eroxon^®, launched by Haleon in the United States, is the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED). The treatment works directly on the penis to stimulate nerve endings leading to increased blood flow to help men get and keep an erection for sex/intimacy. Eroxon^® is a convenient and accessible ED treatment for millions of men. For more information, please visit our website eroxon.us.

About Haleon U.S.
Haleon (NYSE: HLN) is a leading global consumer health company with a purpose to deliver better everyday health with humanity.  Haleon's product portfolio spans five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Wellness. Built on trusted science, innovation, and deep human understanding, Haleon's U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com. 

1. Selvin E, Burnett A, Platz E Prevalence and risk factors for erectile dysfunction in the U S Am Jour of Med 2007 (120) 151-157
2. National Institutes of Health (NIH) website http://kidney niddk nih gov/kudiseases/pubs/ED/index aspx Downloaded 5/14/12
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61. doi: 10.1016/s0022-5347(17)34871-1. PMID: 8254833.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haleon-announces-the-launch-of-eroxon-the-first-and-only-fda-cleared-otc-gel-for-erectile-dysfunction-available-for-us-preorder-without-a-prescription-302235236.html

SOURCE Haleon

FAQ

When will Eroxon be available in U.S. stores for Haleon (HLN) stock investors?

Eroxon will be available in most major U.S. retailers in October 2024. It is currently available for pre-order on Amazon.

How quickly does Haleon's (HLN) Eroxon work compared to existing ED treatments?

Eroxon is clinically proven to help men get an erection within 10 minutes, while existing prescription solutions may take up to an hour to work, according to their labels.

Is Haleon's (HLN) Eroxon FDA approved for over-the-counter use?

Yes, Eroxon is the first and only FDA-cleared over-the-counter gel for the treatment of erectile dysfunction in the United States.

What is the target market for Haleon's (HLN) new Eroxon product?

Eroxon targets the millions of men in the U.S. affected by erectile dysfunction, including those experiencing ED due to physical conditions or psychological challenges such as stress and anxiety.